Jiangsu Hengrui Pharmaceuticals, which is a China-based pharmaceutical company that is focused on research, development, and manufacturing, as well as the commercialization of innovative medicines, has gone on to enter into two continuing connected transactions with Hansoh Pharma as well as its subsidiary, therefore looking at expanding the development along with the commercialization of the specific drug products within mainland China. As per a 20-year licensing agreement that was signed on 26 December 2025, Hengrui goes on to grant Hansoh Pharma an exclusive license so as to develop and manufacture as well as commercialize a designated product within the PRC, in return for upfront, milestone, and also royalty payments that are in parallel.
As per the 20-year licensing agreement, Chengdu Suncadia, which is Hangrui’s subsidiary, has agreed on a commercialization services framework along with Jiangsu Hansoh, as per which the latter is going to offer non-exclusive commercialization services when it comes to an entrusted product. Due to the fact that Hansoh Pharma is controlled by the Hengrui chairman’s spouse, both deals are classified as two continuing connected transactions as per the Hong Kong listing rules, thereby triggering reporting along with annual review requirements; however, they are exempt from independent approval of shareholders, while the unusually long 20-year term in terms of the licensing deal calls for an opinion from an independent financial adviser on market practice, highlighting a heightened governance scrutiny when it comes to investors along with other stakeholders.
It is well to be noted that Jiangsu Hengrui is listed in Hong Kong and operates within the domestic PRC pharmaceutical market and also partners with industry peers in order to expand its product portfolio along with commercial reach.
